#GLP-1

Novo Nordisk is navigating two departures at once, including the retirement of GLP-1 pioneer Lotte Bjerre Knudsen and the loss of an obesity leader to Boehringer Ingelheim.

A study announced by the 23andMe Research Institute identified genetic predictors tied to both GLP-1 weight-loss efficacy and side effects, highlighting a possible path toward more personalized obesity treatment.

Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.

Structure Therapeutics reports encouraging Phase 2 results for its oral GLP-1 receptor agonist, advancing a pill-form alternative to injectable weight-loss and diabetes drugs.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.

Eli Lilly launches a program to make it easier for employers to add GLP-1 weight loss and diabetes drugs to their health plans, addressing a major coverage gap.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.

With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.